Clara's AI reads your full chart against every GLP-1 label, then matches the molecule to your indication and the formulary most likely to cover it.
Get started How it worksClara auto-syncs from 150,000+ doctors' offices, hospitals, labs, pharmacies, and wearables. Before anything is prescribed, the AI reads your A1C trend, BMI, medication list, eGFR, thyroid and family history against the semaglutide and tirzepatide labels. Free, no credit card.
Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Wegovy and Zepbound are approved for chronic weight management. Clara matches the molecule to your indication and flags which option your formulary is most likely to cover. A licensed physician signs off on the prescription.
Clara writes branded FDA-approved medication to your regular pharmacy, where it may be covered by your insurance. DTC competitors like Hims and Lemonaid run a cash-pay model (and often pivot to 503A compounded semaglutide), which keeps the medication off your health plan entirely.
The right molecule for your indication, flagged against your formulary.
Get started Free to connect your records. No credit card.Once-weekly injectable GLP-1 agonist, FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with T2D and established cardiovascular disease1. Not approved for chronic weight management.
Same molecule as Ozempic, titrated higher (to 2.4 mg/week). FDA-approved for chronic weight management in adults with BMI ≥30, or BMI ≥27 with a weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia3.
Once-weekly dual GIP/GLP-1 agonist, FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes2. The dual-agonist mechanism typically produces larger A1C and weight reductions than semaglutide alone.
Same molecule as Mounjaro. FDA-approved for chronic weight management, and for moderate-to-severe obstructive sleep apnea in adults with obesity4. Titrates from 2.5 mg to 15 mg weekly.
Once-daily oral semaglutide, FDA-approved for type 2 diabetes5. A reasonable option if an injectable is a non-starter, with the caveat that the absorption window is narrow: 30 minutes before the first food, drink, or oral medication of the day.
Oral first-line therapy for type 2 diabetes. Most patients on a GLP-1 for T2D stay on metformin; it's cheap, well-studied, and tends to blunt the cardiovascular and renal risk stack. Clara reconciles both scripts against your eGFR and B12 before calling in the prescription.
| Clara | Hims & Hers | Lemonaid Health | Your doctor | |
|---|---|---|---|---|
| 24/7 AI clinical chat | ✓ Unlimited | Async Care Team messaging | Async provider messaging | ✗ |
| Matches the GLP-1 to your FDA-approved indication | ✓ Every prescription | Weight-loss channel only | Per-category intake | Depends on visit length |
| Cost to start chatting | Free | $39 first-month membership | Brief eligibility assessment | $150+ copay per visit |
| Membership cost | From $25/mo cash-pay (HSA/FSA eligible); medication billed separately, may be covered by your insurance | $149/mo after first month; medication bundled, cash-pay | $49/mo; medication billed separately, cash-pay | Per-visit copay |
| Branded Wegovy written to your pharmacy | ✓ | From $199/mo cash on top of membership | Sold alongside compounded semaglutide, cash-pay | ✓ |
| Branded Mounjaro / Zepbound written to your pharmacy | ✓ | From $1,899/mo cash on top of membership | Zepbound vials or compounded tirzepatide, cash-pay | ✓ |
| Prescription may be covered by your insurance | ✓ | ✗ | ✗ | ✓ |
| Cross-condition reasoning (BP, lipids, thyroid, drug interactions) | ✓ | Single-condition | Per-intake siloes | In theory, rarely in 15 minutes |
| Full primary care, not just weight loss | ✓ | Single-category | Partial, separate intakes | ✓ |
| Labs and biomarkers included in membership | Up to 108 on Concierge | Extra cost | Extra cost | Copay per test |
Branded semaglutide and tirzepatide through your pharmacy, not cash-pay compounded.
Get started HSA/FSA eligible. Licensed in all 50 states.The real mistakes in GLP-1 care are almost never about the molecule. They're about what else is in your record: the family history of medullary thyroid cancer nobody asked about, the statin that's silently pushing your liver enzymes, the insulin dose that starts causing hypoglycemia the week Mounjaro lands, the formulary rule that makes Wegovy free while Zepbound costs you $1,800.
Ozempic is not Wegovy. Mounjaro is not Zepbound. Clara reads your A1C, BMI, and comorbidity list against each label and flags which GLP-1 is actually on-label for you, then picks the variant most likely to be covered by your formulary.
Medullary thyroid cancer family history, MEN 2, pancreatitis history, diabetic retinopathy, eGFR trend, pregnancy plans, concurrent insulin or sulfonylurea. Clara runs the full label contraindication list in seconds. A 15-minute visit physically cannot.
Clara watches your home glucose, your A1C, your weight trajectory, and your GI-side-effect pattern, and flags exactly when to step from 0.25 mg to 0.5 mg to 1 mg (or 2.5 mg to 5 mg to 7.5 mg on tirzepatide). Repeat labs are on-clock, not at the next annual visit.
Every GLP-1 label, read against your full chart in seconds.
Get started Free to start. Membership from $25/month, HSA/FSA eligible.Start free. Connect your records. See what happens when an AI reads every GLP-1 label against your full chart before anything is prescribed.
Get started